Climb Bio Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Aoife Brennan

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

CEO

Aoife Brennan (48 yo)

no data

Permanencia

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President and Director at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) Dr. Brennan serves as Director of Xilio Therapeutics...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Aoife Brennan	CEO, President & Director	no data	sin datos	sin datos
Brett Kaplan	COO & Principal Financial Officer	less than a year	sin datos	sin datos
Emily Pimblett	Chief Accounting Officer	1.8yrs	sin datos	0.011% $ 26.6k
Jo Palmer-Phillips	Chief Development Officer	no data	sin datos	sin datos
Nishi Rampal	Senior Vice President of Clinical Development	less than a year	sin datos	sin datos

0.3yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CLYM no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Aoife Brennan	CEO, President & Director	no data	sin datos	sin datos
Adam Rosenberg	Independent Director	4.1yrs	US$77.16k	0.27% $ 626.9k
Liam Ratcliffe	Lead Independent Director	5.1yrs	US$71.33k	0% $ 0
Simon Tate	Independent Director	5.8yrs	US$22.52k	0% $ 0
Andrew Levin	Co-Founder & Chairman	5.8yrs	US$87.91k	0% $ 0
Stephen Thomas	Director	less than a year	sin datos	0.15% $ 365.8k
Judith Dunn	Independent Director	3.8yrs	US$69.66k	0% $ 0

4.6yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de CLYM se considera experimentada (4.6 años de antigüedad promedio).

Climb Bio Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Recent updates

Climb Bio, Inc. Present Additional Data from the Completed Pmn Trial and Share Clinical Data from A Single Patient with Minimal Change Disease (Mcd) Treated with Budoprutug

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. (NasdaqGM:ELYM) completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics, Inc. announced that it has received $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad